Schreml, Julia and Gouni-Berthold, Ioanna (2018). Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance. Curr. Med. Chem., 25 (13). S. 1538 - 1549. SHARJAH: BENTHAM SCIENCE PUBL LTD. ISSN 1875-533X
Full text not available from this repository.Abstract
Statin intolerance is usually defined as the inability of a patient to tolerate statin-treatment due to muscle-related complaints. While randomised trials show that these complaints occure with similar frequency in patients receiving placebo, namely in up to similar to 5% of the subjects, and data from registries as well as clinical experience indicate a much higher frequency of up to similar to 30%. The lack of standard definition or of a diagnostic marker of statin intolerance confounds the problem. The diagnosis remains subjective based on the symptoms the patient reports. Therefore, a large number of patients who need a statin are not receiving it, or receiving only very-low and/or intermittent doses unable to achieve a robust decrease in low-density lipoprotein cholesterol (LDL-C), leaving patients at high or very high risk for cardiovascular events requiring an alternative form of lipid-lowering therapy. Until recently, the only available alternatives were niacin, ezetimibe, bile-acid sequestrants and fibrates that decrease LDL-C concentrations by up to 15-20%. Recently the fully human monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (PCSK9), alirocumab (Praluent (R)) and evolocumab (Repatha (R)), which have been shown to decrease LDL-C by up to 70% have been approved in Europe for use in patients with primary hypercholesterolemia not at LDL-C target while on maximally tolerated lipid-lowering therapy and specifically for patients with statin intolerance and in the USA for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia requiring additional LDL-C lowering. Ongoing large clinical trials with cardiovascular endpoints will provide a definitive answer for the role of anti-PCSK9 antibodies in clinical practice.
Item Type: | Journal Article | ||||||||||||
Creators: |
|
||||||||||||
URN: | urn:nbn:de:hbz:38-202791 | ||||||||||||
DOI: | 10.2174/0929867324666170616111647 | ||||||||||||
Journal or Publication Title: | Curr. Med. Chem. | ||||||||||||
Volume: | 25 | ||||||||||||
Number: | 13 | ||||||||||||
Page Range: | S. 1538 - 1549 | ||||||||||||
Date: | 2018 | ||||||||||||
Publisher: | BENTHAM SCIENCE PUBL LTD | ||||||||||||
Place of Publication: | SHARJAH | ||||||||||||
ISSN: | 1875-533X | ||||||||||||
Language: | English | ||||||||||||
Faculty: | Unspecified | ||||||||||||
Divisions: | Unspecified | ||||||||||||
Subjects: | no entry | ||||||||||||
Uncontrolled Keywords: |
|
||||||||||||
Refereed: | Yes | ||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/20279 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |